Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
02 2021
Historique:
received: 20 12 2020
revised: 20 01 2021
accepted: 03 02 2021
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 5 3 2021
Statut: ppublish

Résumé

Vaccination against SARS-CoV-2 has become available and will hopefully end the current pandemic. Understandably, patients with inflammatory rheumatic diseases (iRMDs) and their physicians are feverishly preoccupied with questions about vaccination and the vaccines against SARS-CoV-2. However, as it will take months before all patients with iRMDs will have access to the vaccines, measures that are taken now in order to increase potential safety and efficacy of the vaccines may impose a risk for the patients with regard to reactivation of their underlying iRMD. The ad hoc commission 'Covid-19' and the board of directors of the German Society for Rheumatology have addressed this topic and have developed considerations, which are intended to answer urgent questions, to take away concerns and fears and to make initial recommendations for patients with iRMDs.

Identifiants

pubmed: 33627439
pii: rmdopen-2020-001553
doi: 10.1136/rmdopen-2020-001553
pmc: PMC7907835
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
JAMA. 2020 Jul 24;:
pubmed: 32706371
RMD Open. 2020 Sep;6(2):
pubmed: 32878994
Ann Rheum Dis. 2020 Jan;79(1):39-52
pubmed: 31413005
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Hendrik Schulze-Koops (H)

Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilians University of Munich, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.

Christof Specker (C)

Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany.

Alla Skapenko (A)

Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilians University of Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH